Medpace (NASDAQ:MEDP) Shares Up 1.6%

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) traded up 1.6% during mid-day trading on Monday . The stock traded as high as $403.12 and last traded at $398.85. 61,611 shares traded hands during trading, a decline of 75% from the average session volume of 247,262 shares. The stock had previously closed at $392.57.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on MEDP shares. Deutsche Bank Aktiengesellschaft began coverage on Medpace in a research report on Monday, March 18th. They issued a “hold” rating and a $395.00 target price on the stock. Robert W. Baird upped their price target on shares of Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $282.00 to $452.00 in a research note on Thursday, February 15th. Guggenheim increased their target price on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Finally, Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and boosted their price target for the company from $340.00 to $450.00 in a research note on Tuesday, April 23rd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $443.00.

Medpace Price Performance

The stock has a 50-day moving average price of $397.69 and a 200-day moving average price of $334.57. The company has a market capitalization of $12.01 billion, a P/E ratio of 39.51, a P/E/G ratio of 1.95 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The business had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. During the same quarter last year, the firm earned $2.27 earnings per share. Medpace’s quarterly revenue was up 17.7% on a year-over-year basis. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 11.23 EPS for the current fiscal year.

Insider Activity at Medpace

In other news, CEO August J. Troendle sold 100,000 shares of the stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the transaction, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at approximately $1,995,940,186.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, VP Susan E. Burwig sold 102 shares of the business’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the sale, the vice president now directly owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO August J. Troendle sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the sale, the chief executive officer now directly owns 4,833,019 shares of the company’s stock, valued at $1,995,940,186.62. The disclosure for this sale can be found here. Insiders have sold 204,442 shares of company stock worth $82,702,867 in the last quarter. Company insiders own 20.30% of the company’s stock.

Hedge Funds Weigh In On Medpace

A number of hedge funds and other institutional investors have recently modified their holdings of MEDP. Arcadia Investment Management Corp MI lifted its stake in Medpace by 40.3% in the first quarter. Arcadia Investment Management Corp MI now owns 101 shares of the company’s stock valued at $41,000 after purchasing an additional 29 shares during the last quarter. Miller Howard Investments Inc. NY lifted its stake in Medpace by 1.3% in the fourth quarter. Miller Howard Investments Inc. NY now owns 3,075 shares of the company’s stock valued at $943,000 after purchasing an additional 39 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its stake in Medpace by 5.3% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 781 shares of the company’s stock valued at $316,000 after purchasing an additional 39 shares during the last quarter. Schulhoff & Co. Inc. raised its holdings in Medpace by 2.0% during the 3rd quarter. Schulhoff & Co. Inc. now owns 2,250 shares of the company’s stock valued at $545,000 after acquiring an additional 45 shares during the period. Finally, Coldstream Capital Management Inc. raised its holdings in Medpace by 5.0% during the 4th quarter. Coldstream Capital Management Inc. now owns 954 shares of the company’s stock valued at $292,000 after acquiring an additional 45 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.